These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22855394)

  • 1. Immunogenicity of a monovalent pandemic influenza A H1N1 virus vaccine with or without prior seasonal influenza vaccine administration.
    Igari H; Watanabe A; Segawa S; Suzuki A; Watanabe M; Sakurai T; Watanabe M; Tatsumi K; Nakayama M; Suzuki K; Sato T
    Clin Vaccine Immunol; 2012 Oct; 19(10):1690-2. PubMed ID: 22855394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China.
    Zhan Y; Yang Z; Li L; Ye D; Wu H; Fu R; Zhao S; Wang Y; Zhou R; Chen R
    Jpn J Infect Dis; 2011; 64(3):190-4. PubMed ID: 21617301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term immunogenicity of the pandemic influenza A/H1N1 2009 vaccine among health care workers: influence of prior seasonal influenza vaccination.
    Song JY; Cheong HJ; Seo YB; Kim IS; Noh JY; Choi WS; Lee J; Jeong HW; Kee SY; Kim WJ
    Clin Vaccine Immunol; 2013 Apr; 20(4):513-6. PubMed ID: 23365206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar immunogenicity of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine.
    Van der Vliet D; Pepin S; Lambert M; Fauchoux N; Donazzolo Y; Dupuy M; Dakowski C; Denis M
    Hum Vaccin; 2010 Oct; 6(10):823-8. PubMed ID: 20935517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a 2009 pandemic influenza A (H1N1) monovalent vaccine in Chinese infants aged 6-35 months: a randomized, double-blind, controlled phase I clinical trial.
    Li YP; Li W; Liang XF; Liu Y; Huang XC; Li CG; Li RC; Wang JZ; Wang HQ; Yin WD
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1297-307. PubMed ID: 23134570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine.
    Gaglani M; Spencer S; Ball S; Song J; Naleway A; Henkle E; Bozeman S; Reynolds S; Sessions W; Hancock K; Thompson M
    J Infect Dis; 2014 Jun; 209(11):1705-14. PubMed ID: 24363436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine.
    Zhou Y; Ng DM; Seto WH; Ip DK; Kwok HK; Ma ES; Ng S; Lau LL; Peiris JS; Cowling BJ
    PLoS One; 2011; 6(11):e27169. PubMed ID: 22102878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees.
    Herrera MT; Gonzalez Y; Juárez E; Hernández-Sánchez F; Carranza C; Sarabia C; Guzman-Beltran S; Manjarrez ME; Muñoz-Torrico M; Garcia-Garcia L; Sada E; Torres M
    BMC Infect Dis; 2013 Nov; 13():544. PubMed ID: 24238117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
    Lu CY; Shao PL; Chang LY; Huang YC; Chiu CH; Hsieh YC; Lin TY; Huang LM
    Vaccine; 2010 Aug; 28(36):5864-70. PubMed ID: 20600484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
    Bai Y; Shi N; Lu Q; Yang L; Wang Z; Li L; Han H; Zheng D; Luo F; Zhang Z; Ai X
    Hum Vaccin Immunother; 2015; 11(7):1648-53. PubMed ID: 26083828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial.
    Vajo Z; Tamas F; Jankovics I
    Clin Vaccine Immunol; 2012 Mar; 19(3):313-8. PubMed ID: 22219315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of inactivated 2009 H1N1 influenza vaccine in pediatric liver transplant recipients.
    Torii Y; Kimura H; Ochi N; Kaneko K; Ando H; Kiuchi T; Ito Y
    Vaccine; 2011 Jun; 29(25):4187-9. PubMed ID: 21513762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-reactive antibody response to the pandemic A (H1N1) 2009 influenza virus induced by vaccination with a seasonal trivalent influenza vaccine: a longitudinal study of three influenza seasons in Japan.
    Uno S; Kimachi K; Matsuo F; Miyazaki K; Oohama A; Kei J; Nishimura T; Odoh K; Kino Y
    Microbiol Immunol; 2012 Dec; 56(12):810-6. PubMed ID: 23009167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.
    Tremblay CL; Rouleau D; Fortin C; Toma E; Sylla M; Cyr L; Cote S; Baz M; Sampalis J; Trautman L; Sékaly RP; Boivin G
    Vaccine; 2011 Feb; 29(7):1359-63. PubMed ID: 21185423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.
    Nolan T; McVernon J; Skeljo M; Richmond P; Wadia U; Lambert S; Nissen M; Marshall H; Booy R; Heron L; Hartel G; Lai M; Basser R; Gittleson C; Greenberg M
    JAMA; 2010 Jan; 303(1):37-46. PubMed ID: 20026597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical trial to assess the immunogenicity and safety of Inactivated Influenza Vaccine (Whole Virion) IP (Pandemic Influenza (H1N1) 2009 Monovalent Vaccine; VaxiFlu-S™) in healthy Indian adult population.
    Kubavat AH; Mittal R; Patel PM; Jarsaniya DH; Pawar PR;
    J Postgrad Med; 2011; 57(2):102-8. PubMed ID: 21654130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine.
    He XS; Sasaki S; Baer J; Khurana S; Golding H; Treanor JJ; Topham DJ; Sangster MY; Jin H; Dekker CL; Subbarao K; Greenberg HB
    J Infect Dis; 2013 Jan; 207(2):288-96. PubMed ID: 23107783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial.
    Viganò A; Giacomet V; Pariani E; Giani E; Manfredini V; Bedogni G; Erba P; Amendola A; Zanetti A; Zuccotti G
    Clin Vaccine Immunol; 2011 Sep; 18(9):1503-9. PubMed ID: 21795458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.